



# The Florida Senate

## Local Funding Initiative Request

### Fiscal Year 2021-2022

LFIR # 1026

1. **Project Title**
2. **Senate Sponsor**
3. **Date of Request**

**4. Project/Program Description**

Oragenics is Florida's only company working on a COVID vaccine. By partnering with another Florida manufacturer to conduct research to pre fill syringes (fill finish). This research will be sent to FDA to prepare the tools for clinical trials which will be conducted in Florida in at risk communities and with the veteran population. Clinical trials cost upwards of \$2.5 million and the \$500,000 request enables the research to place the vaccine in the syringe.

Unlike current messenger RNA, the vials are no longer available. The goal is to create options for vaccines as we have learned that at least 10 may be needed to supply the demand.

5. **State Agency to receive requested funds**
- State Agency contacted?**

**6. Amount of the Nonrecurring Request for Fiscal Year 2021-2022**

Type of Funding	Amount
Operations	500,000
Fixed Capital Outlay	0
<b>Total State Funds Requested</b>	<b>500,000</b>

**7. Total Project Cost for Fiscal Year 2021-2022 (including matching funds available for this project)**

Type of Funding	Amount	Percentage
Total State Funds Requested (from question #6)	500,000	25%
<b>Matching Funds</b>		
Federal	0	0%
State (excluding the amount of this request)	0	0%
Local	0	0%
Other	1,500,000	75%
<b>Total Project Costs for Fiscal Year 2021-2022</b>	<b>2,000,000</b>	<b>100%</b>

8. **Has this project previously received state funding?**

Fiscal Year (yyyy-yy)	Amount		Specific Appropriation #	Vetoed
	Recurring	Nonrecurring		

9. **Is future funding likely to be requested?**
- a. **If yes, indicate nonrecurring amount per year.**
- b. **Describe the source of funding that can be used in lieu of state funding.**
-



# The Florida Senate

## Local Funding Initiative Request

### Fiscal Year 2021-2022

LFIR # 1026

**10. Has the entity requesting this project received any federal assistance related to the COVID-19 pandemic?**

Yes

**If yes, indicate the amount of funds received and what the funds were used for.**

Orogenics is working with BARDA, the Department of Defense and other federal agencies on funding. Orogenics applied for WARP speed funding and will continue to pursue this opportunity once processes are determined.

**11. Details on how the requested state funds will be expended**

Spending Category	Description	Amount
<b>Administrative Costs:</b>		
Executive Director/Project Head Salary and Benefits		0
Other Salary and Benefits		0
Expense/Equipment/Travel/Supplies/Other		0
Consultants/Contracted Services/Study		0
<b>Operational Costs: Other</b>		
Salary and Benefits		0
Expense/Equipment/Travel/Supplies/Other	The money will be used to conduct the mouse immunogenicity study demonstrating that the vaccine candidate Terra-CoV 2 generates an appropriate immune response. The study will be included in the FDA Investigational New Drug (IND) application later in 2021. The study will be conducted at a third party vendor, Experimur.	500,000
Consultants/Contracted Services/Study		0
<b>Fixed Capital Construction/Major Renovation:</b>		
Construction/Renovation/Land/Planning Engineering		0
<b>Total State Funds Requested (must equal total from question #6)</b>		<b>500,000</b>

**12. Program Performance**

**a. What specific purpose or goal will be achieved by the funds requested?**

The goal will be for a Florida company to take a COVID vaccine to market. Orogenics acquisition in March, 2020 of a University of Florida research park company, allowed Orogenics to take the NIH recognized spike protein to the next level of development. This \$500,000 will provide the next step to begin clinical trials in Black and Brown communities and in the veteran communities.

**b. What activities and services will be provided to meet the intended purpose of these funds?**

Research and in lab collaboration to ensure the vaccine does not leak from the syringe and that it can be quickly administered.

**c. What direct services will be provided to citizens by the appropriation project?**



# The Florida Senate

## Local Funding Initiative Request

### Fiscal Year 2021-2022

LFIR # 1026

Florida is in a particularly unique situation as it relates to the supply and demand for a COVID vaccine. The thousands of seniors in and OUT of nursing homes are a primary target. Ease of administration has recently been shown to be difficult.

This funding will allow for those obstacles to be removed and provide a quick delivery of the vaccine. Additionally, Florida's visitors present an opportunity to keep Floridians safe.

**d. Who is the target population served by this project? How many individuals are expected to be served?**

Citizens of Florida ages 18 and older.  
Depending on the production and approval cycles after Phase III clinical trials, Oragenics is poised to produce the needed supply to complement other vaccines.

**e. What is the expected benefit or outcome of this project? What is the methodology by which this outcome will be measured?**

The benefit is to vaccinate as many Floridians as possible.  
The methodology of measurement is scientific and will abide by all CDC and FDA guidance.

**f. What are the suggested penalties that the contracting agency may consider in addition to its standard penalties for failing to meet deliverables or performance measures provided for the contract?**

Oragenics is willing to have further discussions and establish deliverables based on knowledge from federal agencies that govern vaccine production.  
Due to the changing dynamics of the pandemic and disease this question requires additional communication.

**13. The owners of the facility to receive, directly or indirectly, any fixed capital outlay funding. Include the relationship between the owners of the facility and the entity.**

NA



# The Florida Senate

## Local Funding Initiative Request

### Fiscal Year 2021-2022

LFIR # 1026

#### 14. Requestor Contact Information

a. First Name  Last Name

b. Organization

c. E-mail Address

d. Phone Number  Ext.

#### 15. Recipient Contact Information

a. Organization

b. Municipality and County

#### c. Organization Type

- For Profit Entity
- Non Profit 501(c)(3)
- Non Profit 501(c)(4)
- Local Entity
- University or College
- Other (please specify)

d. First Name  Last Name

e. E-mail Address

f. Phone Number

#### 16. Lobbyist Contact Information

a. Name

b. Firm Name

c. E-mail Address

d. Phone Number